Acumen Pharmaceuticals
ABOS
52 hedge funds and large institutions have $173M invested in Acumen Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
283% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 6
27% more funds holding
Funds holding: 41 → 52 (+11)
3.8% more ownership
Funds ownership: 59.43% → 63.23% (+3.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
52% less capital invested
Capital invested by funds: $357M → $173M (-$184M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.85M |
| 2 |
BlackRock
New York
|
+$2.65M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$951K |
| 4 |
HF
HRT Financial
New York
|
+$900K |
| 5 |
E
Ergoteles
New York
|
+$848K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.46M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.68M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$2.56M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.03M |
| 5 |
MCM
Moore Capital Management
New York
|
-$122K |
ABOS Hedge Fund Activity: Q4 2021 in Review
52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2021, worth a combined $173M — down 52% from $357M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ABOS positions and 1 closed out — a net gain of 12 holders — while 23 added to existing stakes and 6 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $2.85M. The largest seller was Vanguard Group, cutting an estimated $8.46M.
- 52 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2021, up from 41 in Q3 2021.
- Funds reported $173M of Acumen Pharmaceuticals stock for Q4 2021, down 52% quarter-over-quarter.
- 13 funds opened new Acumen Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +12 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2021 was Goldman Sachs, an estimated $2.85M added.
- The largest Acumen Pharmaceuticals seller in Q4 2021 was Vanguard Group, an estimated $8.46M sold.
Based on aggregated 13F filings for Q4 2021.